Cue Biopharma, Inc. (NASDAQ:CUE)
Cue Biopharma, Inc. (NASDAQ:CUE) represented a move of 0 percent or $-0.1 per share and closed its previous day trading session at $5. 0 Shares were traded in the last trading session with an Average Volume of 95.61 Million Shares. The stock currently has a Market Capitalization of 105.45 Million.
Cue Biopharma, Inc. is an immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. Cue Biopharma, Inc. is headquartered in Cambridge, Massachusetts.
The stock traded between $ 4.47 and $17.99 over 1-Year time period showing its price to sales ratio of 131.81. Cue Biopharma, Inc. (NASDAQ:CUE) is currently showing an DECREASING volatility over a period of 10-Days while the 20-Days Volatility showing a DECREASING trend.
Right now, the stock has a 50-Day Simple Moving Average of $-25.25 and 200-Day Simple Moving Average of $-54.14. Its Price to Free Cash Flow is 0 and Price to Book of 2.55.
Analyst’s recommended the stock as 2 where 1 represents Strong Buy and 5 represents Sell.
In the last Quarter, Cue Biopharma, Inc. (NASDAQ:CUE) reported its Actual EPS of $-0.62/share. The analysts offering Earnings Estimates for the company were believing that Cue Biopharma, Inc. could bring EPS of $-0.38/share. The difference between Actual EPS and Estimated EPS was -0.24 Percent. Thus showing an Earnings Surprise of -63.2 Percent.
Cytosorbents Corporation (NASDAQ:CTSO)
In the last trading session, Cytosorbents Corporation (NASDAQ:CTSO) added its value by 0% closing at the price of $9.94. The stock currently has market capitalization of 320.37 Million, with average volume of 201.15 Million shares.
Beta is also a factor of measure of the relative volatility of a particular stock to the market. Currently Cytosorbents Corporation (NASDAQ:CTSO) is showing beta of 0.53. This particular value of beta suggests that Cytosorbents Corporation (NASDAQ:CTSO) has historically moved 53% for every 100% move in the benchmark, based on price level.
EPS is another important factor while making the decision of buying, selling or holding of particular share. Currently EPS for Cytosorbents Corporation (NASDAQ:CTSO) is at $-0.5.
The stock currently has RSI of 44.13. RSI is considered overbought when above 70 and oversold when below 30, currently the given RSI for the stock suggests that the stock is average and it has not entered in overbought or oversold territory.
CytoSorbents Corporation is a therapeutic medical device company. It develops adsorbent polymer technology for applications in the medical field, primarily to provide blood purification for the treatment of acute and chronic health complications associated with blood toxicity. The Company’s product include CytoSorb, which filters cytokines and treat potentially fatal cytokine storm and BetaSorb, which remove beta2-microglobulin from the blood of patients suffering from chronic kidney failure. CytoSorbents Corporation is headquartered in Monmouth Junction, New Jersey.
Cytosorbents Corporation (NASDAQ:CTSO) topped its 52-week high price of $14.95 on 08/30/18 and 52-Week Low Price of $ 5.80 on 12/13/17. The Stock currently has P/E (price to earnings ttm) of 0 and Weekly volatility of 5.10% and monthly volatility of 7.35% respectively.